Dividend Overview
Dividend Yield
—
Dividend / Share
—
Arrowhead Pharmaceuticals Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Did you know?
Capital expenditures decreased by 84% from FY24 to FY25.
Current Price
$74.81
+1.81%Profile
Valuation (TTM)
Market Cap$10.16B
P/E50.23
EV—
P/B21.80
Shares Out135.81M
P/Sales9.31
Revenue$1.09B
EV/EBITDA29.30
Arrowhead Pharmaceuticals Inc (ARWR) Dividends
Key Metrics
Market Cap
$10.16B
P/E Ratio
50.23
Forward P/E
—
EPS
$-0.01
PEG Ratio
-0.43
Book Value
$3.43
Dividend Yield
—
Profit Margin
18.54%
ROE
43.40%
Dividend History
Dividend Safety
ARWR Dividend Analysis
Arrowhead Pharmaceuticals Inc (ARWR) dividend analysis including yield, payout history, and sustainability metrics.
P/E ratio: 50.23. Profit margin: 18.54%. Free cash flow: $156.89M. This page shows Arrowhead Pharmaceuticals Inc's dividend overview, key metrics, historical payout data, and dividend safety assessment to help income-focused investors evaluate the sustainability of dividend payments.
GoodMoat's dividend analyzer evaluates payout ratios, earnings coverage, and free cash flow coverage to determine how well supported Arrowhead Pharmaceuticals Inc's dividend payments are. Use this analysis alongside the company's financial statements and quality score to make informed income-investing decisions.